CorMedix (CRMD) Q1 2026 Earnings Transcript

CorMedix reported Q1 net revenue of $127.4 million, up sharply from $39.1 million a year ago, with adjusted EBITDA rising to $70 million from $23.6 million and net income increasing to $38.6 million. Management raised full-year revenue guidance to $325 million-$345 million and adjusted EBITDA guidance to $115 million-$135 million, while also boosting DefenCath revenue guidance to $175 million-$195 million. The REZZAYO Phase III trial met its primary endpoint, supporting an sNDA filing in 2H26, though the TPN study remains delayed with completion now trending into 2028.

Analysis

CRMD is transitioning from a single-product reimbursement story into a cash-generative, two-asset platform, but the market is likely still underappreciating how much of the near-term equity debate is now about reimbursement mechanics rather than demand. The key second-order effect is that the 2026 setup intentionally compresses optics in H2 to set up a cleaner 2027 step-up; if utilization holds while ASP resets higher, consensus could be forced to model a much steeper revenue inflection than the current guide implies. That makes the stock less about Q2/Q3 print risk and more about whether patient retention survives the June/July pricing transition.

The REZZAYO data materially de-risks the pipeline and, more importantly, changes the strategic value of the commercial infrastructure the company is building. Even before launch, the option value is greater than the headline probability of approval because a positive prophylaxis label would put CRMD into a high-acuity hematology/transplant channel where DefenCath relationships may create selling leverage and lower customer-acquisition cost. The market may be missing that the real synergy is not product overlap, but shared access to the same institutional decision-makers, which can reduce future G&A intensity per dollar of revenue.

The biggest bear case is not efficacy, but execution latency: TPN is slipping into 2028, and any setback on the FDA amendment would keep that program as a long-dated option with limited near-term valuation support. Also, the reported cash generation is flattered by working-capital timing and nonrecurring allowance changes, so the cleaner read is that operating leverage is real but not yet fully linear. If H2 DefenCath utilization softens more than management expects, the multiple could de-rate quickly because the market is currently paying for a smooth reimbursement transition that may not exist.

Key Decisions for Investors

• Long CRMD into the next 1-2 quarters on pullbacks; thesis is that reimbursement-driven volatility will be a buying opportunity if utilization remains intact. Risk/reward improves if the stock trades down on Q2 seasonality while 2027 price-reset visibility increases.
• Buy CRMD Jan/Apr 2027 calls and finance with near-dated calls or puts around the H2 reimbursement transition. This expresses the view that the market is underpricing the 2027 gross profit re-acceleration if patient volumes hold.
• Pair trade: long CRMD / short a basket of slower-growth hospital-infection or specialty pharma names with weaker balance sheets. CRMD should outperform if investors rotate toward self-funded commercial platforms with visible cash generation and pipeline optionality.
• Use any sharp post-print rally to trim into strength until FDA feedback on the REZZAYO filing and the TPN amendment are de-risked. The setup is bullish, but the stock can overshoot on narrative and then retrace on timing risk.
• Do not chase the stock solely on REZZAYO headline success; wait for the actual sNDA pathway and label-framing clarity. The catalyst is real, but the monetization timeline is still months away and could be the source of valuation compression if delayed.